Missouri seeks to marketplace pain-free dental tool

Scientist Meng Chen says he expects tellurian clinical trials to start in early 2012 during a University of Tennessee’s Memphis campus. Chen is arch scientist for Nanova Inc., a association shaped by several professors that shares a obvious on a new record with a university.

Article source: http://www.boston.com/news/education/higher/articles/2011/12/30/missouri_seeks_to_market_pain_free_dental_tool

BIOLASE Issued Broad New Patent for Treating Eye Conditions, Including Presbyopia, Cataracts and Glaucoma

IRVINE, CA–(Marketwire -11/30/11)- BIOLASE Technology, Inc. (NASDAQ: BLTI – News), a World’s heading dental laser manufacturer and distributor, currently announced that a U.S. Patent and Trademark Office has released BIOLASE a new obvious covering a use of a laser technologies for treating several conditions of a eye. The obvious covers a design and techniques for treating an visible or associated hankie site utilizing laser appetite to impact one or some-more physiological properties mitigating a effects of presbyopia and improving a approach a chairman sees.

Patent 8,056,564 is patrician “Methods for Treating Eye Conditions” and supports a ophthalmic patents previously

Article source: http://finance.yahoo.com/news/BIOLASE-Issued-Broad-New-iw-2876389802.html

BIOLASE to Present during Upcoming Investment Conferences

IRVINE, CA–(Marketwire -11/29/11)- BIOLASE Technology, Inc. (NASDAQ: BLTI – News), a World’s heading dental laser manufacturer and distributor, announced currently that government is scheduled to make financier presentations during dual arriving investment conferences.

The initial discussion will be CANACCORD Genuity’s 6th Annual Cardiovascular, Aesthetics Metabolic Disorders Conference on Tuesday, Dec 6, during that COO and CFO Fred Furry is scheduled to benefaction during 10:00 am Pacific Time. The one-day discussion is being hold during a St. Regis Hotel in San Francisco.

A live audio webcast of a display during a CANACCORD Genuity Conference will be accessible in

Article source: http://finance.yahoo.com/news/BIOLASE-Present-Upcoming-iw-1863038741.html

BIOLASE to Present during Lazard Capital Markets Healthcare Conference

IRVINE, CA–(Marketwire -11/09/11)- BIOLASE Technology, Inc. (NASDAQ: BLTI – News), a World’s heading dental laser manufacturer and distributor, announced currently that COO CFO Fred Furry is scheduled to make an financier display during Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, Nov 16, during 2:30 pm Eastern Time. The discussion is being hold Nov 15-16 during a Pierre Hotel in New York City.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., a World’s heading Dental Laser company, is a medical record association that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products

Article source: http://finance.yahoo.com/news/BIOLASE-Present-Lazard-iw-1667381731.html

BIOLASE Chief Financial Officer Frederick D. Furry to Add Chief Operating Officer Role

IRVINE, CA–(Marketwire – Oct 19, 2011) – BIOLASE Technology, Inc. (NASDAQ: BLTI), a World’s heading dental laser manufacturer and distributor, announced currently that Chief Financial Officer Frederick D. Furry has been allocated to Chief Operating Officer, effective immediately. Furry will continue in his purpose as Chief Financial Officer and reports directly to Chief Executive Officer Federico Pignatelli.

“Fred has been instrumental in a turnaround efforts during BIOLASE over a past year, and broadening his responsibilities to embody operations will concede him to move even some-more value to a organization,” pronounced Pignatelli. “Both we and a Board have each certainty that Fred’s

Article source: http://www.marketwire.com/mw/release.do?id=1575147&sourceType=3

BIOLASE International Laser Sales Exceed United States Laser Sales in a Third Quarter

IRVINE, CA–(Marketwire – Oct 13, 2011) – BIOLASE Technology, Inc. (NASDAQ: BLTI), a World’s heading dental laser manufacturer and distributor, currently announced that in a third entertain finished Sep 30, 2011, general laser sales exceeded a historically stronger United States marketplace laser sales. Management allocated a Company’s offered resources to these building markets in sequence to take advantage of new general regulatory approvals that combined marketplace opportunities for a Company’s new flagship product, a Waterlase iPlus™ all-tissue dental laser system, in Canada, Russia, and Taiwan.

Federico Pignatelli, Chairman and CEO, stated, “The squeeze of a Waterlase iPlus by general dentists

Article source: http://www.marketwire.com/mw/release.do?id=1572702&sourceType=3